Hospital Nuestra Senora De Sonsoles

Avila 9 trials 1 recruiting

9 Registered trials

1 Currently recruiting

Organisation

Hospital Nuestra Senora De Sonsoles

Location

Avila, Spain

Identifier

ORG-100048532

Address

Avenida De Juan Carlos I Sn, 05004, Spain

Departments

Allergology
Allergy
N/A
Oncology
Preventive medicine service
Servicio de Oncología

Clinical trials at this site (9)

Search interface

Dose-ranging study evaluating the efficacy and safety of EVO756 in adults with Chronic Spontaneous Urticaria. Pending

2024-518786-10-01 Moderate to Severe Chronic Spontaneous Urticaria 4
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Pending

2025-521709-42-00 Allergic rhinoconjunctivitis with or without asthma due 5
Grass Immunotherapy for Rhinitis and Asthma (GIRA) Pending

2025-521736-10-00 Allergic rhinoconjunctivitis with or without controlled 5
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergy Ended

2024-514525-34-00 Aetiological treatment of moderate-severe intermitent o 5 2024-08-18
A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi… Ended

2023-509516-28-00 Stage II/Stage III rectal cancer or Stage II (high risk 4 2021-02-22
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell … Ended

2023-507902-15-00 Non-Small Cell Lung Cancer 4 2019-03-26
A study on the immune response, safety and the occurrence of RSV-associated respiratory tract illness after administration of RSV OA vaccine… Ended

2023-509455-13-00 Respiratory Syncytial Virus Infections 11 2024-08-05
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Non-resectable locally advanced or metastatic HER2-posi 9 2023-03-08